Page last updated: 2024-11-13

cytidylyl-3'-5'-guanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cytidylyl-3'-5'-guanosine: also referred to as CpG [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135508734
SCHEMBL ID8616145
MeSH IDM0065292

Synonyms (17)

Synonym
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl [(2r,3s,4r,5r)-5-(4-amino-2-oxo-pyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl] hydrogen phosphate
phosphoric acid 5-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester 5-(4-amino-2-oxo-2h-pyrimidin-1-yl)-4-hydroxy-2-hydroxymethyl-tetrahydro-furan-3-yl ester
2382-65-2
einecs 219-186-1
cytidine monophosphate guanosine
cytidylyl-(3',5')-guanosine
cg-dinucleotide
cytidylyl-3'-5'-guanosine
cytosine-guanine dinucleotide
SCHEMBL8616145
cytidylyl (3'-5')guanosine
(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2r,3s,4r,5r)-3,4-dihydroxy-5-(2-imino-6-oxo-2,3-dihydro-1h-purin-9(6h)-yl)tetrahydrofuran-2-yl)methyl hydrogen phosphate
guanosine cytidine 3',5'-monophosphate
cytidylylguanosine
DTXSID601315872
STARBLD0009560
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"X chromosome inactivation is a mechanism of dosage compensation that regulates the expression of mammalian X-linked genes between XY males and XX females."( 2.6 Mb YAC contig of the human X inactivation center region in Xq13: physical linkage of the RPS4X, PHKA1, XIST and DXS128E genes.
Brown, CJ; Chelly, J; Chinault, AC; Lafrenière, RG; Monaco, AP; Rider, S; Taillon-Miller, P; Willard, HF, 1993
)
0.29
" We conclude that effective DC-based therapy of a poorly immunogenic TS/A tumor is enhanced by optimized dosing of CpG DNA."( Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice.
Baar, J; Cai, Q; Cumberland, R; Gooding, W; Kublo, L, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
(3'->5')-dinucleotideAny dinucleotide where the two components are connected via a (3'->5')-phosphodiester linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (754)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (5.97)18.7374
1990's413 (54.77)18.2507
2000's202 (26.79)29.6817
2010's79 (10.48)24.3611
2020's15 (1.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.26%)5.53%
Reviews41 (5.24%)6.00%
Case Studies6 (0.77%)4.05%
Observational0 (0.00%)0.25%
Other733 (93.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]